Skip to main content

Unrecognized diabetes in critically ill COVID-19 patients

Dear Editor,

Since the first discovery of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and description of the coronavirus disease 2019 (COVID-19), a pandemic has evolved. Due to winter tourism, Tyrol, a federal province of Austria with 750,000 inhabitants, has emerged as an epicenter in Austria being faced with a surge of critically ill COVID-19 patients reaching its peak on April 8, 2020.

We retrospectively analyzed the incidence of diabetes in all critically ill patients admitted to the four dedicated COVID-19 intensive care units (ICU) at the University Hospital in Innsbruck, Tyrol, Austria, which covers 180,000 inhabitants as primary hospital and also functions as a tertiary referral center for the whole region of Tyrol. Patients were included in the analysis if they were 18 years of age or older, had confirmed COVID-19, and were admitted to an intensive care unit from March 11 to April 29, 2020. COVID-19 was confirmed by reverse-transcriptase-polymerase-chain-reaction assays of nasopharyngeal swab specimens. Data were abstracted manually from electronic and paper-based health records. Glycated hemoglobin (HbA1c) was measured on admission by high-performance liquid chromatography (HPLC-UV/VIS).

Of 47 COVID-19 patients admitted to our ICUs, HbA1c was measured in 44, which were included in the analysis (Table 1). The median age of patients was 61.5 (IQR 53.0–68.0). Thirty-five (80%) patients required invasive mechanical ventilation (IMV). Additionally, 4 patients (9%) required veno-venous extracorporeal membrane oxygenation (vvECMO). At the time of writing this article, 11 patients (25%) have died in the hospital, 25 (56.8%) have been discharged alive from the ICU, 20 patients (45.5%) were discharged alive from the hospital, and 13 patients (29.5%) are still hospitalized.

Table 1 Characteristics of included patients, stratified by HbA1c

Median HbA1c was 6.5% (IQR 6.1–6.7%). When categorizing patients according to HbA1c [1], 24 (54.5%) were considered to have diabetes mellitus (HbA1c ≥ 6.5%), 16 (36.3%) were considered to have prediabetes (HbA1c ≥ 5.7% < 6.5%), and only 4 (9%) had no diabetes (HbA1c < 5.7%). Interestingly, only 7 (15.9%) patients showed a medical history of diabetes mellitus. Five (11.4%) patients had previously been treated with antidiabetic medication, and no patient had required insulin prior to hospitalization. Patients with increased HbA1c levels developed higher maximum CRP and IL-6 levels during their ICU stay. There was a trend to higher in-hospital mortality with increasing HbA1c.

The median body mass index (BMI) was 29.4 kg/m2 (IQR 26.2–32.7), which is slightly higher than a previously studied sample of critically ill patients in Austria [2], with a median BMI of 26 kg/m2. BMI did not differ significantly between diabetic and non-diabetic patients (Fig. 1).

Fig. 1
figure1

Correlation between body mass index (BMI) [kg/m2] and glycated hemoglobin (HbA1c) [%]

In conclusion, 85% of COVID-19 treated in our intensive care units had prediabetes and diabetes which appear to be predisposing factors for severe manifestations of COVID-19, potentially impairing outcome. This is in line with previous observations from the first SARS-CoV epidemic [3]. Hyperglycemia may alter the response of the innate immune system through several mechanisms. It may induce Toll-like receptor expression and inhibit neutrophil function, decrease vascular dilation, and increase permeability [4]. Furthermore, it can cause direct glycosylation of proteins, thereby altering the structure of complement, and may cause a cytokine storm [4, 5]. Recent data demonstrating viral particles in endothelial cells of several organs suggest “endotheliitis” as a possible mechanism of organ dysfunction leading to critical illness in COVID-19 patients which may be aggravated by endothelial dysfunction associated with prediabetes and diabetes [6]. More pronounced peak levels of inflammation observed in our patients with abnormal HbA1c may support such an assumption. In conclusion, we recommend routine measurement of HbA1c in hospitalized COVID-19 patients for additional risk stratification, because most patients of our cohort were previously not diagnosed with having impaired glucose tolerance.

Availability of data and materials

No data is publicly available at this time.

References

  1. 1.

    World Health Organization. Use of glycated haemoglobin (HbA1c) in diagnosis of diabetes mellitus: abbreviated report of a WHO consultation. https://www.who.int/cardiovascular_diseases/report-hba1c_2011_edited.pdf. Published 2011. Accessed 04 May 2020.

  2. 2.

    Roth D, Meyer L, Bickell F, et al. P002 - Atemwegsmanagement an einer von Internisten geführten Notaufnahme. Medizinische Klinik - Intensivmedizin und Notfallmedizin. 2012;107:301–40.

    Article  Google Scholar 

  3. 3.

    Yang JK, Feng Y, Yuan MY, et al. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabet Med. 2006;23(6):623–8.

    CAS  Article  Google Scholar 

  4. 4.

    Jafar N, Edriss H, Nugent K. The effect of short-term hyperglycemia on the innate immune system. Am J Med Sci. 2016;351(2):201–11.

    Article  Google Scholar 

  5. 5.

    Wang Q, Fang P, He R, et al. O-GlcNAc transferase promotes influenza A virus–induced cytokine storm by targeting interferon regulatory factor–5. Sci Adv. 2020;6(16):eaaz7086.

    Article  Google Scholar 

  6. 6.

    Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417–8.

    CAS  Article  Google Scholar 

Download references

Acknowledgements

We would like to thank Romuald Bellmann, Robert Breitkopf, Christoph Hochhold, Andreas Peer, Christian Preuß Hernández, and Mathias Ströhle for their support in conducting this analysis.

Funding

No funding was received for this study.

Author information

Affiliations

Authors

Contributions

SJK, SK, and MJ collected data and wrote the manuscript. DF, SM, and CT collected data for this study. The author(s) read and approved the final manuscript.

Corresponding author

Correspondence to Michael Joannidis.

Ethics declarations

Ethics approval and consent to participate

This study was approved by the ethics committee of the Medical University Innsbruck (# 1099/2020).

Consent for publication

Not applicable—the manuscript contains no individual patient data.

Competing interests

None of the authors have any conflicts of interest to declare.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Klein, S.J., Fries, D., Kaser, S. et al. Unrecognized diabetes in critically ill COVID-19 patients. Crit Care 24, 406 (2020). https://doi.org/10.1186/s13054-020-03139-3

Download citation